ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

被引：59

作者：

Fizazi, Karim ^{[1
]}

Albiges, Laurence ^{[1
]}

Loriot, Yohann ^{[1
]}

Massard, Christophe ^{[1
]}

机构：

[1] Univ Paris Sud, Dept Canc Med, Inst Gustave Roussy, F-94800 Villejuif, France

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 09期

关键词：

androgen receptor inhibitors; castration resistant; efficacy; metastatic; non-metastatic; ODM-201; pharmacodynamics; pharmacokinetics; prostate cancer; tolerability; PROGRESSION-FREE SURVIVAL; ACETATE PLUS PREDNISONE; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; DOUBLE-BLIND; OPEN-LABEL; CLINICAL ACTIVITY; PHASE-III; DOCETAXEL; ENZALUTAMIDE;

D O I：

10.1586/14737140.2015.1081566

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has formed the basis for a new generation of agents targeting the AR axis. Two of these agents, abiraterone acetate and enzalutamide, have been shown to prolong overall survival in patients with CRPC. Several other AR inhibitors are currently in development for the treatment of CRPC. The present article reviews ODM-201, a new-generation AR inhibitor with a unique molecular structure, in the treatment of CRPC. The design of an ongoing Phase III trial (ARAMIS) of ODM-201 in men with non-metastatic CRPC is also discussed, at a disease stage for which there is currently no approved treatment.

引用

页码：1007 / 1017

页数：11

共 55 条

[1] Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies [J].

Al Nakouzi, Nader ;

Le Moulec, Sylvestre ;

Albiges, Laurence ;

Wang, Chris ;

Beuzeboc, Philippe ;

Gross-Goupil, Marine ;

Rouge, Thibault de la Motte ;

Guillot, Aline ;

Gajda, Dorota ;

Massard, Christophe ;

Gleave, Martin ;

Fizazi, Karim ;

Loriot, Yohann .

EUROPEAN UROLOGY, 2015, 68 (02) :228-235

[2]

[Anonymous], Head and Neck Cancers NCCN Guidelines

[3] AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Wang, Hao ;

Luber, Brandon ;

Nakazawa, Mary ;

Roeser, Jeffrey C. ;

Chen, Yan ;

Mohammad, Tabrez A. ;

Chen, Yidong ;

Fedor, Helen L. ;

Lotan, Tamara L. ;

Zheng, Qizhi ;

De Marzo, Angelo M. ;

Isaacs, John T. ;

Isaacs, William B. ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038

[4] Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate [J].

Attard, Gerhardt ;

de Bono, Johann S. ;

Logothetis, Christopher J. ;

Fizazi, Karim ;

Mukherjee, Som D. ;

Joshuas, Anthony M. ;

Schrijvers, Dirk ;

van den Eertwegh, Alfons J. M. ;

Li, Weimin ;

Molina, Arturo ;

Griffin, Thomas W. ;

Kheoh, Thian ;

Ricci, Deborah S. ;

Zelinsky, Kathy ;

Rathkopf, Dana E. ;

Scher, Howard I. ;

Ryan, Charles J. .

CLINICAL CANCER RESEARCH, 2015, 21 (07) :1621-1627

[5]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[6] ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment [J].

Clegg, Nicola J. ;

Wongvipat, John ;

Joseph, James D. ;

Tran, Chris ;

Ouk, Samedy ;

Dilhas, Anna ;

Chen, Yu ;

Grillot, Kate ;

Bischoff, Eric D. ;

Cal, Ling ;

Aparicio, Anna ;

Dorow, Steven ;

Arora, Vivek ;

Shao, Gang ;

Qian, Jing ;

Zhao, Hong ;

Yang, Guangbin ;

Cao, Chunyan ;

Sensintaffar, John ;

Wasielewska, Teresa ;

Herbert, Mark R. ;

Bonnefous, Celine ;

Darimont, Beatrice ;

Scher, Howard I. ;

Smith-Jones, Peter ;

Klang, Mark ;

Smith, Nicholas D. ;

De Stanchina, Elisa ;

Wu, Nian ;

Ouerfelli, Ouathek ;

Rix, Peter J. ;

Heyman, Richard A. ;

Jung, Michael E. ;

Sawyers, Charles L. ;

Hager, Jeffrey H. .

CANCER RESEARCH, 2012, 72 (06) :1494-1503

[7] CCP score and risk stratification for prostate cancer patients at biopsy [J].

Crawford, E. David ;

Shore, Neal ;

Scardino, Peter T. ;

Davis, John W. ;

Tward, Jonathan D. ;

Harrison, Lowndes ;

Moyes, Kelsey ;

Fitzgerald, Lisa ;

Stone, Steven ;

Brawer, Michael K. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)

[8] Circulating Tumor Cells as Biomarkers in Prostate Cancer [J].

Danila, Daniel C. ;

Fleisher, Martin ;

Scher, Howard I. .

CLINICAL CANCER RESEARCH, 2011, 17 (12) :3903-3912

[9] Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer [J].

Danila, Daniel C. ;

Morris, Michael J. ;

de Bono, Johann S. ;

Ryan, Charles J. ;

Denmeade, Samuel R. ;

Smith, Matthew R. ;

Taplin, Mary-Ellen ;

Bubley, Glenn J. ;

Kheoh, Thian ;

Haqq, Christopher ;

Molina, Arturo ;

Anand, Aseem ;

Koscuiszka, Michael ;

Larson, Steve M. ;

Schwartz, Lawrence H. ;

Fleisher, Martin ;

Scher, Howard I. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) :1496-1501

[10] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

← 1 2 3 4 5 6 →